Clinical manifestations of oral lymphomas – Retrospective study of 15 cases in a Taiwanese population and a review of 592 cases from the literature

Tseng, Chiu‐yu; Wang, Wen-Chen; Chen, Ching-Yi; Hsu, Han-Jen; Chen, Yuk-Kwan

doi:10.1016/j.jfma.2020.05.025

Cited by 13 publications

(8 citation statements)

References 31 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Non-Hodgkin’s lymphoma (NHL) is the seventh common malignancy in the United States, mostly regarded as a malignancy with good prognoses and 5-year survival of approximately 70%. The most common types of NHL are diffuse large B cell lymphoma (DLBCL), follicular lymphoma (FL), and mantle cell lymphoma (MCL) ( 1 ). The typical therapeutic methods for lymphoma include radiation therapy, chemotherapy, immunotherapy, and so on.…”

Section: Introductionmentioning

confidence: 99%

RETRACTED: A Deep Insight Into CAR-T Cell Therapy in Non-Hodgkin Lymphoma: Application, Opportunities, and Future Directions

et al. 2021

View full text Add to dashboard Cite

Non-Hodgkin’s lymphoma (NHL) is a cancer that starts in the lymphatic system. In NHL, the important part of the immune system, a type of white blood cells called lymphocytes become cancerous. NHL subtypes include marginal zone lymphoma, small lymphocytic lymphoma, follicular lymphoma (FL), and lymphoplasmacytic lymphoma. The disease can emerge in either aggressive or indolent form. 5-year survival duration after diagnosis is poor among patients with aggressive/relapsing form of NHL. Therefore, it is necessary to understand the molecular mechanisms of pathogenesis involved in NHL establishment and progression. In the next step, we can develop innovative therapies for NHL based on our knowledge in signaling pathways, surface antigens, and tumor milieu of NHL. In the recent few decades, several treatment solutions of NHL mainly based on targeted/directed therapies have been evaluated. These approaches include B-cell receptor (BCR) signaling inhibitors, immunomodulatory agents, monoclonal antibodies (mAbs), epigenetic modulators, Bcl-2 inhibitors, checkpoint inhibitors, and T-cell therapy. In recent years, methods based on T cell immunotherapy have been considered as a novel promising anti-cancer strategy in the treatment of various types of cancers, and particularly in blood cancers. These methods could significantly increase the capacity of the immune system to induce durable anti-cancer responses in patients with chemotherapy-resistant lymphoma. One of the promising therapy methods involved in the triumph of immunotherapy is the chimeric antigen receptor (CAR) T cells with dramatically improved killing activity against tumor cells. The CAR-T cell-based anti-cancer therapy targeting a pan–B-cell marker, CD19 is recently approved by the US Food and Drug Administration (FDA) for the treatment of chemotherapy-resistant B-cell NHL. In this review, we will discuss the structure, molecular mechanisms, results of clinical trials, and the toxicity of CAR-T cell-based therapies. Also, we will criticize the clinical aspects, the treatment considerations, and the challenges and possible drawbacks of the application of CAR-T cells in the treatment of NHL.

show abstract

Section: Introductionmentioning

confidence: 99%

RETRACTED: A Deep Insight Into CAR-T Cell Therapy in Non-Hodgkin Lymphoma: Application, Opportunities, and Future Directions

et al. 2021

View full text Add to dashboard Cite

show abstract

“…[7] In contrast to our current case, the most common site of oral lymphoma involvement was the gingiva, and the most frequent symptoms were pain, swelling, ulceration, paresthesia, and palpable lymph nodes. [8] The International Prognostic Index (IPI) is a scoring system for predicting overall survival which evaluates the patient by age, stage, lymph node involvement, serum lactate dehydrogenase level, and performance status. According to this scoring system, our patient scored 1 point which was identified as a low-intermediate risk.…”

Section: Discussionmentioning

confidence: 99%

Peripheral T-cell Lymphoma of the oral cavity: a case report

Asadi

Mahmoudi

mofidi

et al. 2021

Preprint

View full text Add to dashboard Cite

show abstract

“…In this retrospective study, soft tissues were more commonly involved than hard tissues by NHL, with greater involvement of buccal mucosa, followed by rare localizations, such as the tongue, gingiva and cheek. Tseng et al have recently reviewed 607 cases of oral lymphomas: concerning location, they found that the most affected site was the gingiva, followed by the palate, maxilla, mandible, tongue, buccal mucosa, vestibule, lip and floor of the mouth [ 33 ]. The rare incidence and the common signs and symptoms in the oral cavity determine important factors for the misdiagnosis of NHL [ 26 , 34 , 35 ].…”

Section: Discussionmentioning

confidence: 99%

“…The etiology is still unknown, but the recent increase in incidence may be related to immunodeficiency conditions. Undoubtedly, immunodeficiency-HIV-related patients have an increased incidence of oral NHL for their systemic complications [ 26 , 33 ]. However, in the southern Italian regions and rural areas, the low risk of HIV infection reduces the incidence of immunodeficiency-related NHL, as reported in this study.…”

Section: Discussionmentioning

confidence: 99%

Oral Malignant Non-Hodgkin Lymphoma: A Retrospective Single-Center Study

Barone

Buffone

Ferrillo

et al. 2022

IJERPH

View full text Add to dashboard Cite

This study aimed to retrospectively evaluate the incidence of oral non-Hodgkin lymphoma (NHL) in patients referred to the Academic Hospital of the Magna Graecia University of Catanzaro from 2002 to 2020. A retrospective single-center study was performed. Patients with a histologically confirmed diagnosis of oral NHL were included. Demographic data and clinical parameters were digitally recorded, focusing on the NHL-specific localization and symptomatology. The study sample was evaluated by analyzing descriptive statistics with absolute and relative frequencies. A total of 26 patients with intraoral NHL were identified with a progressive increase in NHL occurrence during the observation period. Clinical manifestations included swelling/mass (80.7%), eventually associated with pain and ulcerations. The most common localizations were in soft tissues: buccal mucosa (38.4%), tongue (19.2%), gingiva (11.5%), cheek (11.5%). Oral NHL is rare. Clinical manifestations were unspecific, so a misdiagnosis could occur. The extranodal B-cell form of oral NHL, particularly diffuse large B-cell lymphoma, was the most common frequent oral NHL in this southern Italian population, with a progressively increased occurrence in almost 20 years.

show abstract

Clinical manifestations of oral lymphomas – Retrospective study of 15 cases in a Taiwanese population and a review of 592 cases from the literature

Cited by 13 publications

References 31 publications

RETRACTED: A Deep Insight Into CAR-T Cell Therapy in Non-Hodgkin Lymphoma: Application, Opportunities, and Future Directions

RETRACTED: A Deep Insight Into CAR-T Cell Therapy in Non-Hodgkin Lymphoma: Application, Opportunities, and Future Directions

Peripheral T-cell Lymphoma of the oral cavity: a case report

Oral Malignant Non-Hodgkin Lymphoma: A Retrospective Single-Center Study

Contact Info

Product

Resources

About